ABSTRACT
Cardiac fibrosis is linked to fibroblast-to-myofibroblast phenoconversion and proliferation but the mechanisms underlying this are poorly understood. Ski is a negative regulator of TGF-β–Smad signaling in myofibroblasts, and might redirect the myofibroblast phenotype back to fibroblasts. Meox2 could alter TGF-β-mediated cellular processes and is repressed by Zeb2. Here, we investigated whether Ski diminishes the myofibroblast phenotype by de-repressing Meox2 expression and function through repression of Zeb2 expression. We show that expression of Meox1 and Meox2 mRNA and Meox2 protein is reduced during phenoconversion of fibroblasts to myofibroblasts. Overexpression of Meox2 shifts the myofibroblasts into fibroblasts, whereas the Meox2 DNA-binding mutant has no effect on myofibroblast phenotype. Overexpression of Ski partially restores Meox2 mRNA expression levels to those in cardiac fibroblasts. Expression of Zeb2 increased during phenoconversion and Ski overexpression reduces Zeb2 expression in first-passage myofibroblasts. Furthermore, expression of Meox2 is decreased in scar following myocardial infarction, whereas Zeb2 protein expression increases in the infarct scar. Thus Ski modulates the cardiac myofibroblast phenotype and function through suppression of Zeb2 by upregulating the expression of Meox2. This cascade might regulate cardiac myofibroblast phenotype and presents therapeutic options for treatment of cardiac fibrosis.
Footnotes
Competing interests
The authors declare no competing interests.
Author contributions
R.H.C. designed the study, generated the adenoviral HA-Ski construct, carried out phenotyping studies and contributed to the initial version of the manuscript. J.M.N. designed the Meox studies, performed qPCR, analyzed data and reviewed the manuscript. S.G., J.J.L.D. and M.S.K. contributed by carrying out the cell proliferation study as well as the tissue fractionation and phenotyping work. K.L.F. and F.J. carried out the Meox and Zeb2 western analyses, as well as the tissue immunofluorescence work. J.T.W and I.M.C.D. provided contributions to experimental design, data analysis and synthesis of the manuscript.
Funding
This work was supported by the Canadian Institutes for Health Research and the Heart and Stroke Foundation of Manitoba (I.M.C.D. and J.T.W.). J.T.W. is a Manitoba Health Research Council Manitoba Research Chair. R.H.C. is the recipient of the MHRC/CIHR RPP doctoral student scholarship. S.G. is a Parker B. Francis scholar in Respiratory Diseases.
- Received January 7, 2013.
- Accepted October 1, 2013.
- © 2014. Published by The Company of Biologists Ltd